Scientists make first crystal model of under-diagnosed autoimmune disease

June 13, 2017
To solve the structure of myasthenia gravis, scientists mixed proteins from the nAChR a1 and myasthenia gravis auto-antibody, to create crystals of the nicotinic acetylcholine receptors, a neuromuscular receptor responsible for movement, as it is disrupted by the autoimmune disease, myasthenia gravis. The crystals were shot with an X-ray (synchrotron, Advanced Photon Source in Chicago) to solve the structure. Credit: USC Chen lab and Advanced Photon Source in Chicago

As a molecular biologist, Kaori Noridomi gets an up-close view of the targets of her investigations. But when she began studying the molecular structures of a rarely diagnosed autoimmune disorder, myasthenia gravis, she decided to step out of the lab for a better view.

Noridomi said she thought she needed to know more than what she saw on a microscope and decided she should meet who have myasthenia gravis. She went so far as to attend a fundraising walk that supported research of the .

"Patients are just waiting for breakthroughs in research and better treatment," said Noridomi, a researcher in Professor Lin Chen's Molecular and Computational Biology lab at the USC Dornsife College of Letters, Arts and Sciences. "They may also, because the disease attacks their immune system, end up with other diseases. I met one patient who had myasthenia gravis and had also dealt with four different types of cancer."

Motivated by the patients' stories, Noridomi and a team of scientists, including Chen, developed a 3-D, of the disease's to fully view its molecular interactions with a neural receptor that is the regular target of the disease. It is the first, high-resolution visual display of the molecular interactions.

The development of the crystal structure gives scientists a clear view of how exactly the disease behaves and interferes with brain-to-muscle signals. The ability to see these interactions will likely accelerate research of the disease and could possibly lead to new disease-targeting therapies, said Lin Chen, the study's corresponding author and a USC Dornsife College professor of biological sciences and chemistry.

"Because of this finding, we may also find a better quantitative way to identify patients," Chen said.

An estimated 36,000 to 60,000 Americans (around 20 per every 100,000) are affected by myasthenia gravis each year. At least, that is the estimated number of patients who receive the diagnosis. The Myasthenia Gravis Foundation of America believes far more have the disease but they are not diagnosed.

Diagnosed patients may end up on therapies that treat one or some of the symptoms - but not the disease itself, said Noridomi, a Ph.D. candidate. The symptoms may range from weakness in the facial muscles and eyes to slurred speech.

Chen, Noridomi and their team of researchers noted in the study that myasthenia gravis is "the first, and so far, only autoimmune disease with a well-defined autoantigen target," alluding to the "" that the disease's malfunctioning antibodies attack.

These are the same kind of receptors that respond to drugs such as nicotine. In the muscles, though, these receptors have a specific job: receive and transmit the brain's orders to contract muscles.

The brain sends those orders in the form of a chemical neurotransmitter, acetylcholine, directing it to the receptors on the skeletal muscles. In a healthy body, once the acetylcholine reaches the receptors on the destined muscle or muscles, it binds with them and causes them to contract.

In a patient with gravis, though, the disease's antibodies jam this process, according to the National Institute of Neurological Disorders and Stroke. The antibodies attack the receptor and try to destroy a protein within it, according to the study.

Myasthenia gravis is most frequently diagnosed by detection of those distinct, rogue antibodies. Scientists first identified as a condition in 1877. The USC scientists noted that the disease's pathology wasn't understood until the 1970s when researchers realized that disease's antibodies were, for the most part, attacking a specific receptor in the muscles.

With the crystal model, the scientists were able to see the disease's interactions with the receptor as if it were frozen as a moment in time. They also saw that it had cross-linked with several to accelerate the degradation of their proteins.

"Our studies suggest it is possible to develop drug molecules to inhibit the binding of a large fraction of MG antibodies" to the receptor," the scientists wrote.

However, scientists remain unsure why some patients experience more severe or widespread symptoms than others.

"It's a little bit of disease and a little bit of heredity that cause this," Noridomi said. "In some people, the level of symptoms may be so slight and varied that they may not even go to the trouble of finding out if they have a disease. By that, I mean, maybe they just don't feel good one day, like they don't feel like going to work. They don't know that ultimately they are suffering an attack."

Noridomi said she believes the team's findings will lead to greater scientific understanding and may give patients long-awaited hope.

"It has been very touching to hear their difficulties," Noridomi said. "Since there is no good treatment right now, they are really waiting for more research to come."

Explore further: New cause found for muscle-weakening disease myasthenia gravis

More information: Kaori Noridomi et al, Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications, eLife (2017). DOI: 10.7554/eLife.23043

Related Stories

New cause found for muscle-weakening disease myasthenia gravis

November 11, 2013
An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report.

New research finds pathogenic connection between autoimmune disorders and cancer

July 22, 2014
Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University (GW) researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22.

New study supports surgery as treatment for myasthenia gravis

August 10, 2016
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients' weakness, and their need for immunosuppressive ...

Treating myasthenia gravis with autologous hematopoietic stem cell transplants

April 4, 2016
A report on seven cases of severe myasthenia gravis (an autoimmune disease characterized by severe muscle weakness) suggests that autologous hematopoietic stem cell transplantation (when a patient's own stem cells are used) ...

Study examines impact of two new antibodies in causing, treating myasthenia gravis

April 5, 2016
A study of patients from across the nation with myasthenia gravis is helping determine the incidence of two new antibodies believed to cause the disease, and whether these patients need different treatment strategies.

Eculizumab shows promise in treating refractory generalized myasthenia gravis (gMG)

July 19, 2016
Newly reported data from a clinical trial led by a UNC School of Medicine researcher show that eculizumab may be helpful in treating treating refractory generalized myasthenia gravis (gMG), an extremely rare neuromuscular ...

Recommended for you

Researchers discover key signaling protein for muscle growth

November 20, 2017
Researchers at the University of Louisville have discovered the importance of a well-known protein, myeloid differentiation primary response gene 88 (MyD88), in the development and regeneration of muscles. Ashok Kumar, Ph.D., ...

New breast cell types discovered by multidisciplinary research team

November 20, 2017
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into the molecular changes that drive breast development.

Brain cell advance brings hope for Creutzfeldt-Jakob disease

November 20, 2017
Scientists have developed a new system to study Creutzfeldt-Jakob disease in the laboratory, paving the way for research to find treatments for the fatal brain disorder.

Hibernating ground squirrels provide clues to new stroke treatments

November 17, 2017
In the fight against brain damage caused by stroke, researchers have turned to an unlikely source of inspiration: hibernating ground squirrels.

Age and gut bacteria contribute to multiple sclerosis disease progression

November 17, 2017
Researchers at Rutgers Robert Wood Johnson Medical School published a study suggesting that gut bacteria at young age can contribute to multiple sclerosis (MS) disease onset and progression.

Molecular guardian defends cells, organs against excess cholesterol

November 16, 2017
A team of researchers at the Harvard T. H. Chan School of Public Health has illuminated a critical player in cholesterol metabolism that acts as a molecular guardian in cells to help maintain cholesterol levels within a safe, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.